NCT02238717View on ClinicalTrials.gov

Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Healthy
Interventions
DRUG

PF-06372865 (65mg)

single oral dose (65 mg)

DRUG

PF-06372865 (15mg)

single oral dose (15mg)

DRUG

Pregabalin

single oral dose (300mg)

DRUG

Placebo

matching oral placebo

Trial Locations (1)

2333

Centre for Human Drug Research, Leiden

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02238717 - Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints | Biotech Hunter | Biotech Hunter